These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 488466)

  • 1. In vivo activity of spleen cells from untreated syngeneic mice against Ehrlich ascites carcinoma.
    Jakóbisiak M; Kawiak J; Kawalec M; Kańtoch M; Kamiński M; Rozmysłowicz T
    Folia Biol (Praha); 1979; 25(3):169-78. PubMed ID: 488466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural cell-mediated cytotoxicity in Ehrlich ascites tumor-bearing mice.
    Olinescu A; Hristescu S; Mazilu E
    Neoplasma; 1983; 30(2):147-52. PubMed ID: 6843720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice.
    Takei F; Levy JG; Kilburn DG
    J Immunol; 1976 Feb; 116(2):288-93. PubMed ID: 814160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of leukemia by nonimmune syngeneic spleen cells.
    Cheever MA; Greenberg PD; Fefer A
    J Immunol; 1980 May; 124(5):2137-42. PubMed ID: 7365249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats.
    Kawase I; Komuta K; Namba M; Yokota S; Ogura T; Kishimoto S
    Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo suppression of Ehrlich ascites carcinoma by human antibody-dependent splenocytes.
    Dobaczewska H
    Neoplasma; 1984; 31(2):165-8. PubMed ID: 6717686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirements for T cells in alloantigen-induced generation of non-T cell-mediated cytotoxicity against syngeneic mouse sarcoma cells.
    Paciucci PA; Macphail S; Bach FH; Zarling JM
    J Immunol; 1980 Jul; 125(1):36-9. PubMed ID: 6155401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
    Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
    Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo elimination by specific effector cells of an established syngeneic rat moloney virus-induced sarcoma.
    Fernandez-Cruz E; Halliburton B; Feldman JD
    J Immunol; 1979 Oct; 123(4):1772-7. PubMed ID: 158055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo modulation of thymus-derived lymphocytes with monoclonal antibodies in mice. III. Spontaneous and natural cytotoxic effector cells.
    Herbert AG; Le Gros GS; Bidawid S; Watson JD
    Immunology; 1984 Feb; 51(2):377-85. PubMed ID: 6607213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in natural killer cells activity in mice bearing subcutaneously implanted Lewis lung carcinoma.
    Budzyński W
    Arch Immunol Ther Exp (Warsz); 1984; 32(2):185-9. PubMed ID: 6487051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation by OK-432 of generation of culture-induced killer cells.
    Ujiie T
    Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on the improved effect of anti-TCR alpha beta monoclonal antibody on the induction of transplantation tolerance to the allogeneic skin graft in mice and its mechanisms].
    Hao J; Liu J; Xie S
    Zhonghua Yi Xue Za Zhi; 2001 May; 81(10):593-6. PubMed ID: 11798930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of in vivo antitumour activity of xenogeneic antiserum by autotransplanted normal spleen cells in mice.
    Jakóbisiak M; Kańtoch M; Lasek W; Rozmysłowicz T; Obłakowski P; Dobaczewska H
    Eur J Cancer (1965); 1981 Jan; 17(1):77-80. PubMed ID: 7262149
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulation of cytotoxic lymphocyte responses in vitro by alloantigen-activated spleen cells.
    Truitt GA; Rich RR; Rich SS
    J Immunol; 1977 Jul; 119(1):31-7. PubMed ID: 874322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice.
    Brunda MJ; Taramelli D; Holden HT; Varesio L
    J Immunol; 1983 Apr; 130(4):1974-9. PubMed ID: 6187831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural immunity to grafts of FLD-3 erythroleukemia cells by irradiated mice.
    Afifi MS; Bennett M; Kumar V
    Nat Immun Cell Growth Regul; 1986; 5(4):200-10. PubMed ID: 2430178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. V. Spleen immunoreactivity and cell mediated cytotoxicity.
    Laatikainen A; Syrjänen K; Mäntyjärvi R; Tosi P
    Arch Geschwulstforsch; 1987; 57(4):265-74. PubMed ID: 3118852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.